KalVista Pharmaceuticals (KALV)

• Market cap: $819M
• 1 day: -4.14%
• 5 days: 0.12%
• 1 month: 9.02%
• 3 months: 20%
• 6 months: 24.23%
• Year to date: 82.84%
• 1 year: 81.01%
• 5 years: -13.14%
• 10 years: -65.46%
• Sector: Healthcare
• Industry: Biotechnology

About: KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Employees: 270